PDS Biotechnology
PDSB
47 hedge funds and large institutions have $15.4M invested in PDS Biotechnology in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 13 closing their positions.
751% more call options, than puts
Call options by funds: $2.05M | Put options by funds: $241K
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
0.42% less ownership
Funds ownership: 18.62% → 18.2% (-0.42%)
8% less funds holding
Funds holding: 51 → 47 (-4)
20% less capital invested
Capital invested by funds: $19.2M → $15.4M (-$3.79M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$1.27M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$370K |
| 3 |
IGGA
Iron Gate Global Advisors
Nsl,
Utah
|
+$318K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$245K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$230K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$608K |
| 2 |
Two Sigma Advisers
New York
|
-$555K |
| 3 |
Millennium Management
New York
|
-$549K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$390K |
| 5 |
Renaissance Technologies
New York
|
-$292K |
PDSB Hedge Fund Activity: Q3 2022 in Review
47 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q3 2022, worth a combined $15.4M — down 20% from $19.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of PDSB and 10 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 14 added.
The largest buyer was LPL Financial, adding an estimated $1.27M. The largest seller was Two Sigma Investments, cutting an estimated $608K.
- 47 institutional investors held PDS Biotechnology (PDSB) as of Q3 2022, down from 51 in Q2 2022.
- Funds reported $15.4M of PDS Biotechnology stock for Q3 2022, down 20% quarter-over-quarter.
- 10 funds opened new PDS Biotechnology positions in Q3 2022 and 13 closed out, a net change of -3 holders.
- The largest PDS Biotechnology buyer in Q3 2022 was LPL Financial, an estimated $1.27M added.
- The largest PDS Biotechnology seller in Q3 2022 was Two Sigma Investments, an estimated $608K sold.
Based on aggregated 13F filings for Q3 2022.